The Coherence Gap in Women's Health — and Why It's an Investor's Moment

Women have never had more healthcare options than they do today. More apps, more point solutions, more specialists, more at-home diagnostics. And yet, paradoxically, many women have never felt more lost in the system.

The tension of abundant options and insufficient coherence  are one of the defining fault lines in women's health right now. And it is exactly the kind of tension that creates opportunity.

More Options. More Noise.

For decades, the central problem in women's healthcare was a lack of access. Specialties like maternal mental health, menopause care, and fertility were either underfunded, under-resourced, or geographically out of reach for the majority of women. The solution, naturally, was to build more: more tools, more apps, more point solutions to fill the gaps.

That effort worked to a point. But a patchwork of disconnected solutions is not the same as a system of care. Today, women influence roughly 80% of household healthcare spending, yet nearly 78% of commercially-insured women struggle to know where to turn for specific health needs. More than half have delayed or skipped at least one healthcare service in the past year due to cost or financial concerns. And 82% of women facing symptoms they cannot make sense of, turn to Google rather than a clinician.

The access gap is real. But a new gap is becoming just as urgent: the coherence gap.

Why Women's Health Cannot Be Treated in Silos

Women's health has never been a single condition in isolation. Hormones affect metabolism. Metabolic health affects fertility. Fertility connects to maternity, which connects to postpartum mental health, which connects to long-term cardiovascular risk. These are not separate journeys; they are one continuous story, told by the same body across decades.

Yet the healthcare system has historically treated each chapter as a separate book, written by a separate author, filed in a separate room. That fragmentation does not just create inconvenience. It drives poorer outcomes, delayed diagnoses, and a quiet erosion of trust in a system that women feel was never fully designed for them.

A World Economic Forum and McKinsey Health Institute report released just this spring underscored the scale of this problem: closing care delivery gaps alone could avert roughly 70,000 adverse events (heart attacks, strokes, heart failure) every year in the US. The women's health gap is not only a care crisis. It is an economic one. It shows up in missed work, reduced productivity, and benefits that employees do not trust or use.

Maven's Move — and What It Signals

Against this backdrop, Maven Clinic's announcement earlier this spring is worth paying close attention to.

Maven, the largest virtual clinic for women's and family health, is now serving more than 28 million covered lives globally. They have launched a direct-to-consumer platform, making its care model available to any woman, regardless of whether her employer or health plan covers it. After a decade of working from within the enterprise healthcare system, Maven is returning to its roots.

The move is telling. It is not simply a product expansion. It is a recognition that the consumer demand is there, the clinical infrastructure is ready, and the moment has arrived to meet women where they are rather than where the system decided they should be.

As Maven founder and CEO Kate Ryder put it at the time of the launch: women have more ways to manage their health today than ever before and less coherence than ever. The answer, in her view, is not another point solution. It is a connected clinic, built around how women's bodies actually work.

Maven's platform now offers integrated access across fertility, hormone care, GLP-1 programs, and virtual care. They have care models that straddle both the enterprise and direct-to-consumer channels. That integration is rare. And it is increasingly what women are demanding.

The Broader Shift: Integration as Competitive Advantage

Maven's move reflects a wider maturation in the femtech and women's health space. Experts tracking the sector increasingly point to the same signal: the era of single-purpose tools is giving way to end-to-end platforms that treat women as whole patients across their lifespan.

Women are, as one analyst put it, getting exhausted by having to build and pay for their own health "stack." The businesses that will win are the ones building smarter, integrated offerings that remove burden rather than add to it.

This shift matters enormously to investors. When the competitive moat in women's health was simply "being present" in an underserved category, many point solutions could thrive. As the category matures, the advantage will go to companies that can deliver clinical coherence at scale, connecting the dots across a woman's health journey in a way that drives measurable outcomes, not just engagement.

That is a more demanding bar to clear. But it is also a more durable one. And it is where the category is clearly heading.

The Investment Case — Right Now

Despite everything the women's health sector represents, only 6% of all private health investments are currently allocated to it. Of that, the majority is concentrated in a narrow band of conditions and early-stage companies.

That gap between the scale of the opportunity and the current level of capital is not a warning sign. It is the opportunity.

The companies that are building toward coherence by connecting care across life stages, integrating data and clinical support, meeting women as they are rather than fitting them into legacy categories, are the ones that will define the next decade of this sector.

At Portfolia, this is not a peripheral thesis. It is central to how we invest.

We are backing companies that understand what women's health actually requires: continuity, integration, and a deep commitment to the lived experience of the patient. Because in a market this large, and this undercapitalized, the investors who recognize coherence as the next frontier are the ones who will generate the most meaningful returns.

And the most meaningful impact.

‍